达格列净片致正常血糖酮症2例分析

doi:10.19803/j.1672-8629.2021.03.13

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (3): 271-273.
DOI: 10.19803/j.1672-8629.2021.03.13

达格列净片致正常血糖酮症2例分析

蔡俊¹, 卫菁², 纪立伟^3,*

¹南京大学医学院附属鼓楼医院药学部,江苏南京 210008;
²南京中医药大学附属江苏省中医院药学部,江苏南京 210029;
³北京医院药学部,国家老年医学中心,北京 100730

出版日期:2021-03-15 发布日期:2021-04-06
通讯作者: ^*纪立伟,女,硕士,主任药师,临床药学。E-mail：pulsa1228@126.com
作者简介:蔡俊,男,硕士,主管药师,老年药学。
基金资助:
江苏省药学会-天晴（连云港）医院药学科研项目（Q2019024）; 南京药学会-常州四药医院药学科研基金（2019YX016）

Two Cases of Euglycemic Diabetic Ketosis Induced by Dapagliflozin Tablets

CAI Jun¹, WEI Jing², JI Liwei^3,*

¹Nanjing Drum Tower Hospital Affiliated to Medical College of Nanjing University, Nanjing Jiangsu 210008, China;
²Jiangsu Province Hospital of TCM Affiliated to Nanjing University of Chinese Medicine, Nanjing Jiangsu 210029, China
³China Beijing Hospital, National Center of Gerontology, Beijing 100730, China

Online:2021-03-15 Published:2021-04-06

摘要/Abstract

摘要： 目的提高医务人员对达格列净片导致正常血糖酮症的警惕,为安全使用达格列净片提供参考。方法分析2例由达格列净片导致正常血糖酮症患者的诊疗经过,结合国内外文献分析,探讨达格列净片导致正常血糖酮症的发生情况以及危险因素。结果 2例有糖尿病酮症病史的患者分别在使用达格列净片52 d和18 d后出现正常血糖酮症,立即停用达格列净片并予胰岛素治疗,患者酮体转阴。结论应重视达格列净片导致正常血糖酮症的风险,特别是在既往有糖尿病酮症病史患者中的使用风险。

关键词: 达格列净片, 正常血糖酮症, 药品不良反应

Abstract: Objective To remind medical staff to be more vigilant about Dapagliflozin tablets-induced euglycemic diabetic ketosis, and provide reference for safe use of Dapagliflozin tablets. Methods The process of diagnosis and treatment of 2 patients with euglycemic diabetic ketosis caused by Dapagliflozin tablets was analyzed, and the incidence and related risk factors were analyzed based on domestic and foreign literature. Results Two patients with a history of diabetic ketosis developed euglycemic diabetic ketosis 52 and 18 days after taking Dapagliflozin tablets, respectively. Dapagliflozin tablets were discontinued immediately and insulin therapy was given. The ketone bodies turned negative. Conclusion Clinicians should be alert to the risk of euglycemic diabetic ketosis induced by Dapagliflozin tablets, especially in patients with a history of diabetic ketosis.

Key words: Dapagliflozin tablets, euglycemic diabetic ketosis, adverse drug reactions

中图分类号:

R994.11

蔡俊, 卫菁, 纪立伟. 达格列净片致正常血糖酮症2例分析[J]. 中国药物警戒, 2021, 18(3): 271-273.

CAI Jun, WEI Jing, JI Liwei. Two Cases of Euglycemic Diabetic Ketosis Induced by Dapagliflozin Tablets[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 271-273.

参考文献

[1] Weng JP.New progress in sodium-glucose cotransporter-2 inhibitors[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2016, 8(11): 645-648.
[2] Ptaszynska A, Hardy E, Johnsson E, et al.Effects of dapagliflozin on cardiovascular risk factors[J]. Postgrad Med, 2013, 125(3): 181-189.
[3] Chilton R, Tikkanen I, Cannon CP, et al.Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2015, 17(12): 1180-1193.
[4] Baptist G.The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors - real-world data[J]. Eur Endocrinol, 2018, 14(1): 17-23.
[5] American Diabetes Association.Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43: 98-110.
[6] National Medical Insurance Administration, Ministry of human resources and Social Security. List of drugs approved for negotiation of national medical insurance in 2019 [EB/OL]. (2019-11-28) [2019-12-15]. http://www.gov.cn/xinwen/2019-11/28/content_5456660. htm.
[7] Pace DJ, Dukleska K, Phillips S, et al.Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy[J]. J Pancreat Cancer, 2018, 4(1): 95-99.
[8] Chinese Society of Endocrinology. Guidelines for prevention and treatment of type 2 diabetes mellitus in China (2017 Edition)[J]. Chin J Diabetes Mellitus(中华糖尿病杂志), 2017, 10(1): 4-67.
[9] Pace DJ, Dukleska K, Phillips S, et al.Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy[J]. J Pancreat Cancer, 2018, 4(1): 95-99.
[10] Burke KR, Schumacher CA, Harpe SE.SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature[J]. Pharmacotherapy, 2017, 37(2): 187-194.
[11] Pereyra AM, Ramírez C, Román R.Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report[J]. Rev Chil Pediatr, 2017, 88(3):404-410.
[12] Lin YH.Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysio-logy and contributing factors[J]. J Formos Med Assoc, 2018, 117(9): 849-854.
[13] FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood[EB/OL]. (2015-05-15) [2019-12-15]. https://wayback.archive-it.org/7993/20170112031553/http://www.fda.gov/Drugs/DrugSafety/ucm446845. htm.
[14] FDA Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections[EB/OL]. (2015-12-04) [2019-12-15]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about.
[15] Blau JE, Tella SH, Taylor SI, et al.Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data[J]. Diabetes Metab Res Rev, 2017, 33(8): 1-14.
[16] Zheng FY, Wu Y, Rao YF, et al.The adverse drug reaction evaluation and case analysis by using Naranjo probability scale[J]. Chin Pharm J(中国药学杂志), 2012. 47(8): 650-652.
[17] Lane S, Paskar D, Hamed S, et al.When guidelines fail: euglycemic diabetic ketoacidosis after bariatric surgery in a patient taking a sodium-glucose cotransporter-2 inhibitor: a case report[J]. A A Pract, 2018, 11(2): 46-48.

达格列净片致正常血糖酮症2例分析

Two Cases of Euglycemic Diabetic Ketosis Induced by Dapagliflozin Tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.